Mnemosyne Pharmaceuticals Lands $250,000 Seed Financing Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=c0ce2576-9291-4953-a4d8-60596d01fe6b&Preview=1 - Date
11/15/2011 - Company Name
Mnemosyne Pharmaceuticals - Mailing Address
Undisclosed Providence, RI 02902 - Company Description
The company is a Providence-based drug discovery venture aiming to develop small molecule therapeutics to treat schizophrenia and other cognitive and neuropsychiatric disorders. - Website
Undisclosed
- Transaction Type
Venture Equity - Transaction Amount
$250,000 - Transaction Round
Seed - Proceeds Purposes
Mnemosyne is currently developing a research platform targeting NMDA receptor function, one of the most impactful signaling mechanisms in the brain. The company is aiming to develop small molecule therapeutics to treat schizophrenia and other cognitive and neuropsychiatric disorders. - M&A Terms
- Venture Investor
Slater Technology Fund
